Ally Bridge Group’s Janux Therapeutics JANX Stock Holding History

Ally Bridge Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-81,292	Closed	-$2.19M	–	33
2025 Q1	$2.19M	Sell	81,292 -9,000	-10%	-$339K	1.98%	22
2024 Q4	$4.83M	Sell	90,292 -18,519	-17%	-$980K	4.14%	9
2024 Q3	$4.94M	Buy	+108,811	New	+$4.73M	2.65%	20

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Ally Bridge Group's JANX Position: Q2 2025 in Review

Ally Bridge Group sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 81,292 shares — an estimated $2.19M sold.

Ally Bridge Group first reported a position in JANX in Q3 2024 and held it in 3 quarters. The position peaked at $4.94M in Q3 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

Ally Bridge Group reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
Ally Bridge Group sold 81,292 Janux Therapeutics shares in Q2 2025, an estimated $2.19M.
Ally Bridge Group first reported a position in Janux Therapeutics in Q3 2024 and held it in 3 quarters.
Ally Bridge Group's Janux Therapeutics position peaked at $4.94M in Q3 2024.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.